The first clinical consensus statement for managing multiple sclerosis (MS) in Australia and New Zealand has been released, ...

Hormonal changes at puberty may trigger disease activity, but DMTs reduced the risk, indicating more aggressive treatment may be warranted.

Cosmos Health Inc. ("Cosmos Health" or the "Company")(NASDAQ:COSM) , a diversified, vertically integrated global healthcare ...

Mikael Simons, MD, a neurologist and researcher at Technical University Munich and the Centre for Neurodegenerative Diseases ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Scott, an internationally recognized neurologist and leader in multiple sclerosis (MS) research and clinical care, has been awarded the 2024 MS Research Award by MS Australia.

Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the onset of MS symptoms. Women with multiple sclerosis (MS) show increased risk ...

A young woman has taken to social media to bring awareness to Multiple sclerosis, often shortened to 'MS' after having been ...